Translational Development Acquisition Corp. 8-K

What Happened

• On June 12, 2026, Translational Development Acquisition Corp. (the “Company”) announced the conversion of 4,657,499 Class B ordinary shares held by its sponsor, TDAC Partners LLC, into 4,657,499 Class A ordinary shares.
• The converted Class A shares carry the same restrictions that applied to the Class B shares before conversion (transfer limits, waiver of redemption rights, and an obligation to vote in favor of an initial business combination), as described in the Company’s December 23, 2024 final prospectus.

Key Details

• Conversion date: June 12, 2026.
• Shares converted: 4,657,499 Class B → 4,657,499 Class A.
• Post-conversion totals: 21,907,499 Class A shares outstanding and 1 Class B share outstanding.
• No cash proceeds, no underwriter, no commission; conversion relied on Section 3(a)(9) exemption (unregistered).
• Trust account and public Class A per-share redemption value were unaffected; redemption value ≈ $10.69 per public share as of June 12, 2026.

Why It Matters

• For investors, the conversion does not change the Company’s cash, trust account assets, or the per-share redemption value of public shares—so it has no immediate financial impact on public holders.
• The conversion increases the sponsor’s holdings in Class A form but those shares remain subject to transfer and redemption waivers and voting obligations, which can affect liquidity and insider voting dynamics around any proposed merger or acquisition.
• The transaction was a private, intra-company conversion using a registration exemption, so no new public offering or dilution occurred.